fox6now

Asthma inhaler to be discontinued in January – here's what patients should know

A popular corticosteroid inhaler used to treat asthma and other conditions is being discontinued, and despite generic versions now available, health experts are warning patients to plan ahead for ...
FiercePharma

GSK 'schemed' FDA's drug-device approval pathway to deflect asthma inhaler generics, lawsuit claims

GSK’s perpetual asthma inhaler updates have kept generics makers chasing a moving target for more than half a century, and it’s patients who are being forced to foot the bill, a new lawsuit filed in a ...
FiercePharma

GSK receives FDA approval for Arnuity™ Ellipta® (fluticasone furoate) in the US for the treatment of asthma

LONDON, Aug. 20, 2014 /PRNewswire/ -- GlaxoSmithKline plc today announced that the FDA has approved Arnuity™ Ellipta ® (fluticasone furoate inhalation powder), a once-daily inhaled corticosteroid (ICS ...
Healio

FDA approves Arnuity Ellipta for young children with asthma

Please provide your email address to receive an email when new articles are posted on . GlaxoSmithKline announced that the FDA has approved Arnuity Ellipta, a once-daily inhaled corticosteroid, for ...
News Medical

Arnuity Ellipta

The full CMI on the next page has more details. If you are worried about using this medicine, speak to your doctor or pharmacist. ARNUITY ELLIPTA contains the active ingredient fluticasone furoate.
FierceBiotech

GSK receives FDA approval for Arnuity™ Ellipta® (fluticasone furoate) in the USA for the treatment of asthma

GlaxoSmithKline plc today announced that the Food and Drug Administration has approved Arnuity™ Ellipta® (fluticasone furoate inhalation powder), a once-daily inhaled corticosteroid (ICS) medicine for ...
Monthly Prescribing Reference

Arnuity Ellipta

Fluticasone furoate 50mcg, 100mcg, 200mcg; per inhalation; dry pwd for oral inhalation. Do not exceed recommended dose. Prescribe a short-acting, inhaled β 2-agonist for acute symptoms; monitor for ...